Arvinas, Inc. Q3 2025 Earnings Recap

ARVN Q3 2025 November 6, 2025

Get alerts when ARVN reports next quarter

Arvinas reported a productive third quarter in 2025, characterized by key clinical updates and advancements in their therapeutic pipeline, positioning the company favorably for upcoming milestones.

Earnings Per Share Beat

$-0.48 vs $-0.75 est.

+36.0% surprise

Revenue Beat

41900000 vs 37262930 est.

+12.4% surprise

Market Reaction

1-Day +4.49%

5-Day +17.14%

30-Day +23.41%

See ARVN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Significant clinical data announced for ARV-102, an oral LRRK2 degrader, showing strong tolerability and promising biomarker reductions in ongoing Phase I trials.
Preclinical data for ARV-806 and ARV-027 highlight progress in developing therapies targeting KRAS G12D mutations and spinal bulbar muscular atrophy, respectively.
Vepdegestrant's NDA is under FDA review with a PDUFA date set for June 5, 2026; plans to partner with Pfizer for commercialization are underway.
Strong cash position extends financial runway into the second half of 2028, providing strategic flexibility for ongoing and future projects.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ARVN on AllInvestView.

Next Q1 2026